Polivkova, V.; Benesova, A.; Zizkova, H.; Koblihova, J.; Curik, N.; Motlova, E.; Klamova, H.; Salek, C.; Machova Polakova, K.

Sensitivity and reliability of DNA-based mutation analysis by allele-specific digital PCR to follow resistant BCR-ABL1-positive cells

[rok vydání 2021, impact factor 11.528 ]

Srutova, K.; Curik, N.; Burda, P.; Savvulidi, F.; Silvestri, G.; Trotta, R.; Klamova, H.; Pecherkova, P.; Sovova, Z.; Koblihova, J.; Stopka, T.; Perrotti, D.; Machova Polakova, K.

BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia

[rok vydání 2018, impact factor 7.570 ]

Curik, N.; Polivkova, V.; Burda, P.; Koblihova, J.; Laznicka, A.; Kalina, T.; Kanderova, V.; Brezinova, J.; Ransdorfova, S.; Karasova, D.; Rejlova, K.; Bakardjieva, M.; Kuzilkova, D.; Kundrat, D.; Linhartova, J.; Klamova, H.; Salek, C.; Klener, P.; Hrusak, O.; Machova Polakova, K.

Somatic mutations in oncogenes are in chronic myeloid leukemia acquired de novo via deregulated base-excision repair and alternative non-homologous end joining

[rok vydání 2021, impact factor 6.244 ]

Jaruskova, M.; Curik, N.; Hercog, R.; Polivkova, V.; Motlova, E.; Benes, V.; Klamova, H.; Pecherkova, P.; Belohlavkova, P.; Vrbacky, F.; Machova Polakova, K.

Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment

[rok vydání 2017, impact factor 6.217 ]

Burda, P.; Vargova, J.; Curik, N.; Salek, C.; Papadopoulos, G.L.; Strouboulis, J.; Stopka, T.

GATA-1 inhibits PU.1 gene via DNA and histone H3K9 methylation of its distal enhancer in erythroleukemia

[rok vydání 2016, impact factor 2.806 ]

Polivkova, V.; Rohon, P.; Klamova, H.; Cerna, O.; Divoka, M.; Curik, N.; Zach, J.; Novak, M.; Marinov, I.; Soverini, S.; Faber, E.; Machova Polakova, K.

Interferon-alpha revisited: individualized treatment management eased the selective pressure of tyrosine kinase inhibitors on BCR-ABL1 mutations resulting in a molecular response in high-risk CML patients

[rok vydání 2016, impact factor 2.806 ]